Clinical Trial Update: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CV301 in combination with PD-1/PD-L1 blockade in locally advanced or metastatic bladder cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CV301 (CV301 vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-04-27